And It's Back to the Drawing Board for PDE9 Inhibition in Heart Failure
(MedPage Today) -- PHOENIX -- The development of a PDE9 inhibitor for heart failure hit a major roadblock, as two phase II placebo-controlled trials were suspected of having tested the wrong dose. In both heart failure with reduced ejection...
Phoenix, Arizona -- A potential heart failure treatment using a PDE9 inhibitor has hit a snag, as trials revealed the wrong dosage was tested. James Udelson, MD from Tufts Medical Center presented findings at the Heart Failure Society of America conference. In both types of heart failure, tovinontrine did not meet expectations for reducing the NT-proBNP marker at week 12.
However, the study did uncover an inverse dose response in one trial. Lower doses of tovinontrine showed more significant reductions in NT-proBNP, suggesting there may be a maximum limit to the benefit of increased cGMP elevation in heart failure patients. The next step is a Phase IIb trial set to begin in 2027, which will test lower doses of tovinontrine in heart failure patients.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
